aTyr Developing Bi-Specific Platform for tRNA Synthetase-derived Targets

San Diego's aTyr and its Hong Kong subsidiary, Pangu Biopharma, are on track to develop bi-specific antibodies to treat diseases with Neuropilin-2 (NRP2) overexpression, including cancer. Pangu is in the middle of a two year program to develop its bispecific platform with funding from a Hong Kong innovation fund. aTyr’s R&D is based on the extracellular function and signaling pathways of tRNA synthetases, a new area of biology. The company believes bispecific antibodies may be effective in binding targets derived from tRNA synthetases. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.